<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01909856</url>
  </required_header>
  <id_info>
    <org_study_id>sim-palonosetron</org_study_id>
    <nct_id>NCT01909856</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy</brief_title>
  <official_title>The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Simcere Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Simcere Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the efficacy and safety of palonosetron in preventing the acute and
      delayed emesis induced by 3-day highly emetogenic chemotherapy. A double-blind, crossover
      design is used and granisetron is the positive control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response(CR) within 24-120 hours after chemotherapy</measure>
    <time_frame>24-120 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CR within 0-120 hours after chemotherapy</measure>
    <time_frame>0-120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR within 0-24 hours after chemotherapy</measure>
    <time_frame>0-24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse events</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Arm1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st cycle Palonosetron, 2nd cycle Granisetron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st cycle Granisetron, 2nd cycle Palonosetron</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron</intervention_name>
    <description>Palonosetron 0.25mg d1,d3</description>
    <arm_group_label>Arm1</arm_group_label>
    <arm_group_label>Arm2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granisetron</intervention_name>
    <description>Granisetron 3mg d1-3</description>
    <arm_group_label>Arm1</arm_group_label>
    <arm_group_label>Arm2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 10mg d1-3</description>
    <arm_group_label>Arm1</arm_group_label>
    <arm_group_label>Arm2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>3-day chemotherapy regimens including cisplatin, cisplatin: 25mg/m2 d1-3</description>
    <arm_group_label>Arm1</arm_group_label>
    <arm_group_label>Arm2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with malignant tumors who can receive 3-day chemotherapy regimens
             defined by the protocol;

          -  The two-cycle sequential chemotherapy must be the same in drugs, dosage, sequence and
             routes of administration;

          -  Patients are prohibited from any other chemotherapy drugs during the study, as well as
             other antiemesis, sedative and psychotropic drugs within 5 days after chemotherapy;

          -  Life expectancy â‰¥ 3 months;

          -  Adequate hematologic function;

          -  Adequate hepatic function;

          -  Adequate renal function;

          -  At least 2 weeks away from the last chemotherapy;

          -  Patients signed written informed consent.

        Exclusion Criteria:

          -  Pregnant or lactating women;

          -  History of anticipatory vomiting;

          -  Radiation therapy on the abdomen or pelvis within one week prior to study entry;

          -  Concomitant use of other drugs which may affect the antiemetic effects (such as
             omeprazole, amifostine, etc.);

          -  Patients with gastrointestinal obstruction;

          -  Patients with severe heart disease, liver or renal disease, or metabolism disorders;

          -  Patients with epilepsy or using sedative or psychotropic drugs;

          -  Patients with diabetes or with contraindication for corticosteroids;

          -  Patients who received antiemetic drugs or experienced nausea or vomiting within 24
             hours prior to study entry;

          -  Patients with brain metastasis or intracranial hypertension;

          -  Hypersensitivity to 5-HT3 receptor antagonist;

          -  Patients with active infection;

          -  Other conditions that the investigator considered as unsuitable for chemotherapy;

          -  Subjects participating in other clinical trials.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiying Yu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2013</study_first_submitted>
  <study_first_submitted_qc>July 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2013</study_first_posted>
  <last_update_submitted>December 2, 2015</last_update_submitted>
  <last_update_submitted_qc>December 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Granisetron</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
    <mesh_term>Emetics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

